Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
Assuntina G. Sacco(University of California San Diego), Ezra E.W. Cohen(University of California San Diego), Francis P. Worden(Georgetown University), Gregory A. Daniels(University of California San Diego), Julie Bykowski(University of California San Diego), Amanda Natsuhara(University of California, San Diego), Kathryn A. Gold(University of California San Diego), Deborah Jean Lee Wong(University of California, Los Angeles), Paul Swiecicki(University of Michigan), Mónica V. Estrada(Vanderbilt University), Alfredo Molinolo(National Institutes of Health), Debanjali Ghosh(University of California, San Diego), Douglas R. Adkins, Wanxing Chai‐Ho(University of California, Los Angeles), Scott M. Lippman(The University of Texas MD Anderson Cancer Center), Karen Messer(University of California, San Diego), Ruifeng Chen(University of California, San Diego), Peter Oppelt(Washington University in St. Louis), Emily Pittman(University of California, San Diego)
Cited by 257
Related Papers
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
Lung Cancer
|New England Journal of Medicine|2008|2.4k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k